Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention

Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis

(2021) Anne H Tavenier et al.   European Heart Journal-Cardiovascular Pharmacotherapy

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

(2020) Jean-Philippe Collet et al.   EUROPEAN HEART JOURNAL

Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD

(2019) Sameer Arora et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

(2019) Juhani Knuuti et al.   EUROPEAN HEART JOURNAL

Ticagrelor with or without Aspirin in High-Risk Patients after PCI

(2019) Roxana Mehran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial

(2019) Mariusz Tomaniak et al.   European Heart Journal-Cardiovascular Pharmacotherapy

Incidence and predictors of bleeding in ACS patients treated with PCI and prasugrel or ticagrelor: An analysis from the RENAMI registry

(2018) Fabrizio D'Ascenzo et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

(2018) Pascal Vranckx et al.   LANCET

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease

(2017) William R. Hiatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dyspnea in patients treated with P2Y12 receptor antagonists: insights from the GReek AntiPlatElet (GRAPE) registry

(2017) Dimitrios Alexopoulos et al.   PLATELETS

Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study

(2016) Usman Baber et al.   AMERICAN HEART JOURNAL

Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention

(2016) Robert W. Yeh et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents

(2016) Usman Baber et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack

(2016) S. Claiborne Johnston et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events

(2016) Marc P. Bonaca et al.   JAMA Cardiology

Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

(2015) Marc P. Bonaca et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1

(2014) Duncan Armstrong et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Adenosine-Mediated Effects of Ticagrelor

(2014) Marco Cattaneo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes

(2014) Ezra A. Amsterdam et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Enhanced Mortality Risk Prediction With a Focus on High-Risk Percutaneous Coronary Intervention

(2013) J. Matthew Brennan et al.   JACC-Cardiovascular Interventions

An Updated Bleeding Model to Predict the Risk of Post-Procedure Bleeding Among Patients Undergoing Percutaneous Coronary Intervention

(2013) Sunil V. Rao et al.   JACC-Cardiovascular Interventions

Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12antagonism

(2013) S. Nylander et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study

(2013) Roxana Mehran et al.   LANCET

Third universal definition of myocardial infarction

(2012) Kristian Thygesen et al.   EUROPEAN HEART JOURNAL

Standardized Bleeding Definitions for Cardiovascular Clinical Trials

(2011) Roxana Mehran et al.   CIRCULATION

Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes

(2011) Robert F. Storey et al.   EUROPEAN HEART JOURNAL

Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model

(2011) J. J. J. van Giezen et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study

(2010) Robert F. Storey et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE